Zea’s unique technology platform allows us to partner with biopharma developers and manufacturers to grow pure, clean, consistent plants to help drive the biopharmaceutical industry’s success.
Globally, there are over 6,300 biopharma products in clinical development (Analysis Group, 2017). According to industry experts, it is estimated that up to 50% of all drugs in development will be biopharmaceuticals (Brazilian Journal of Microbiology, 2016). These plant-derived medicines are fast-growing, with a US growth rate that is 10x the growth rate of conventional medicines. While regulatory rigor still exists, biopharmaceuticals can have fewer hurdles to launch.